Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver ...

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and ...

Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of ...

Vertex Pharmaceuticals and Orna Therapeutics announce a $4 billion collaboration to develop in vivo gene editing therapies ...

Stocks like SH Kelkar and Company, Ashoka Buildcon, Vodafone Idea, Bharti Airtel, Coal India, Power Grid Corporation, Nuvoco ...

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

About four years after launch, Orna Therapeutics Inc. signed its second major deal, this time validating the lipid nanoparticle delivery technology it acquired through its Renagade Therapeutics Inc.